Epidemiological studies have clearly established that human papillomavirus (HPV) infection is the major risk factor for cervical cancer. Most cervical cancers and pre-cancers are HPV- positive. Not all pre-cancers pro...Epidemiological studies have clearly established that human papillomavirus (HPV) infection is the major risk factor for cervical cancer. Most cervical cancers and pre-cancers are HPV- positive. Not all pre-cancers progress to cancer; a significant number regress. The immunological basis for either spontaneous or treatment-mediated recovery from HPV-associated CIN is not clear. Currently, prophylactic vaccines are successfully inducing antibody responses in HPV negative patients. The rapeutic vaccines for HPV-positive patients with disease are needed. There is a need to understand the immunologic basis for the Cell-Mediated Immune (CMI) response and for histological regression to help the formulation of therapeutic vaccines. Material and methods. Four groups of women were identified for this cross-sectional study of CMI. Group 1 consisted of six women without cytological or histological diagnosis of CIN and with an HPV negative test (CIN(- )/HPV (- )). Group 2 included 31 women with a new histological diagnosis of CIN and HPV positive test (CIN(+ )/HPV(+ )). Groups 3 and 4 were selected from women who had undergone ablative or excisional treatment for CIN at the colposcopy clinic at least 6 months before the study. The women in groups 3 and 4 were (CIN(+ )/HPV(+ )) before CIN treatment. Group 3 consisted of 22 women without evidence of recurrence of CIN (Recur (- )), and group 4 included 10 with histological diagnosis of recurrent CIN (Recur(+ )). In particular, we investigated CMI responses to synthetic peptides from the E6 and E7 oncoproteins of HPV- 16. Results. Compared to patients with disease recurrence (Recur(+ ), n = 10), the majority of individuals who remained recurrence-free post-treatment (Recur(- ), n = 22) exhibited significant proliferative responses to synthetic peptides from the E6 (P = 0.001) and the E7 (P = < 0.001). In particular, significant responses were observed with the E6 peptide Q15L (aa 43- 57, P = 0.006) and the E7 peptide Q19D (aa 44- 62, P = 0.002) in Recur (- ) patients but not Recur(+ ) individuals. Additionally, PBMC from women in the Recur(- ) group, but not the Recur (+ ) group, produced predominantly TH1 cytokines upon stimulation with the peptides Q15L or Q19D. Conclusions. These results indicate an association between significant cellular immune responses specific to synthetic peptides from the E6 and E7 oncoproteins of HPV- 16 and recurrence-free survival in HPV patients treated for CIN. We predict that these peptides may be useful as indicators of protective immunity for recovery from CIN and also for potential inclusion in designing immunotherapeutic and immunoprophylactic reagents for HPV-associated CIN.展开更多
文摘Epidemiological studies have clearly established that human papillomavirus (HPV) infection is the major risk factor for cervical cancer. Most cervical cancers and pre-cancers are HPV- positive. Not all pre-cancers progress to cancer; a significant number regress. The immunological basis for either spontaneous or treatment-mediated recovery from HPV-associated CIN is not clear. Currently, prophylactic vaccines are successfully inducing antibody responses in HPV negative patients. The rapeutic vaccines for HPV-positive patients with disease are needed. There is a need to understand the immunologic basis for the Cell-Mediated Immune (CMI) response and for histological regression to help the formulation of therapeutic vaccines. Material and methods. Four groups of women were identified for this cross-sectional study of CMI. Group 1 consisted of six women without cytological or histological diagnosis of CIN and with an HPV negative test (CIN(- )/HPV (- )). Group 2 included 31 women with a new histological diagnosis of CIN and HPV positive test (CIN(+ )/HPV(+ )). Groups 3 and 4 were selected from women who had undergone ablative or excisional treatment for CIN at the colposcopy clinic at least 6 months before the study. The women in groups 3 and 4 were (CIN(+ )/HPV(+ )) before CIN treatment. Group 3 consisted of 22 women without evidence of recurrence of CIN (Recur (- )), and group 4 included 10 with histological diagnosis of recurrent CIN (Recur(+ )). In particular, we investigated CMI responses to synthetic peptides from the E6 and E7 oncoproteins of HPV- 16. Results. Compared to patients with disease recurrence (Recur(+ ), n = 10), the majority of individuals who remained recurrence-free post-treatment (Recur(- ), n = 22) exhibited significant proliferative responses to synthetic peptides from the E6 (P = 0.001) and the E7 (P = < 0.001). In particular, significant responses were observed with the E6 peptide Q15L (aa 43- 57, P = 0.006) and the E7 peptide Q19D (aa 44- 62, P = 0.002) in Recur (- ) patients but not Recur(+ ) individuals. Additionally, PBMC from women in the Recur(- ) group, but not the Recur (+ ) group, produced predominantly TH1 cytokines upon stimulation with the peptides Q15L or Q19D. Conclusions. These results indicate an association between significant cellular immune responses specific to synthetic peptides from the E6 and E7 oncoproteins of HPV- 16 and recurrence-free survival in HPV patients treated for CIN. We predict that these peptides may be useful as indicators of protective immunity for recovery from CIN and also for potential inclusion in designing immunotherapeutic and immunoprophylactic reagents for HPV-associated CIN.
